IPP Bureau
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
By IPP Bureau - January 23, 2024
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
AstraZeneca Pharma India receives permission to import new drug
By IPP Bureau - January 22, 2024
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
By IPP Bureau - January 22, 2024
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Novo Holdings expands portfolio in cancer diagnostics
By IPP Bureau - January 22, 2024
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy
By IPP Bureau - January 22, 2024
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg
By IPP Bureau - January 20, 2024
This product has sales of about US$ 20 million in Europe
AbbVie launches Produodopa for treatment of parkinson's disease in EU
By IPP Bureau - January 20, 2024
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
By IPP Bureau - January 19, 2024
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Lupin receives USFDA’s approval for Febuxostat Tablets
By IPP Bureau - January 19, 2024
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
By IPP Bureau - January 19, 2024
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
By IPP Bureau - January 18, 2024
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
NATCO invests US$ 2 million in Cellogen Therapeutics
By IPP Bureau - January 18, 2024
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Taro announces merger agreement with Sun Pharma
By IPP Bureau - January 18, 2024
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Torque Pharma reinvents healthcare dynamics with 'Better Together'
By IPP Bureau - January 18, 2024
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Indoco Remedies receives EIR from USFDA for Goa Plant-I
By IPP Bureau - January 18, 2024
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
